Author: Dr Delwyn Dyall-Smith FACD, Dermatologist, 2010.
X-linked hyper-IgM syndrome (OMIM 308230) is a genetic immunodeficiency syndrome that presents with bacterial and opportunistic infections from an early age. It is the most common form of hyper-IgM syndrome, accounting for approximately 70% of cases. An old name for this condition was dysgammaglobulinaemia type I with neutropenia.
X-linked hyper-IgM syndrome is a rare condition, with an estimated incidence of approximately 1 case per million population.
X-linked hyper-IgM syndrome only affects males, as the defective gene is located on the X chromosome. It is inherited from the mother who is an asymptomatic carrier. Diagnosis is usually made before the age of 12 months when the male infant presents with unusual or severe infections. There may be a family history of unexplained deaths in male infants.
The genetic defect involves the gene on chromosome Xq26 coding for CD40 ligand. This molecule is expressed on activated CD4+T lymphocytes and is involved in switching B cells from making IgM antibodies to IgG and other forms of antibody. So although the problem presents as an inability of B cells to make an appropriate antibody response to infections, the defect is on T cells.
This condition typically presents as unusual, opportunistic or severe infections of upper and lower respiratory or gastrointestinal tracts and is often associated with failure to thrive and enlarged lymph nodes.
The dermatological signs include frequent and recurrent bacterial and fungal skin infections and oral ulcers.
Systemic infection with skin manifestations include cryptococcosis and histoplasmosis. Primary skin infection may be bacterial including cellulitis or viral including treatment-resistant warts, cold sores (herpes simplex)
Oral ulcers are usually not due to infections although these should be excluded. Characteristics of the ulcers include:
Other features of this condition include:
Early diagnosis is important as untreated X-linked hyper-IgM syndrome is fatal.
The initial investigations for a patient suspected of having an immunodeficiency syndrome include immunoglobulin (antibody) levels in the blood.
In X-linked hyper-IgM syndrome:
Specific investigations for X-linked hyper-IgM syndrome are:
These tests will distinguish X-linked hyper-IgM syndrome from the rarer autosomal recessive CD40-deficient syndrome, which is clinically identical. In addition, ataxia-telangiectasia can present as a hyper-IgM syndrome in infancy with the neurological symptoms and telangiectasia developing later in childhood. Congenital rubella, cancer and anti-eplileptic medications may also cause a hyper-IgM pattern of immunodeficiency.
Carrier state diagnosis should be performed on both parents, expecting the mother to have one copy of the same gene mutation (and one normal gene), and the father to have one normal gene. Prenatal diagnosis is available.
Monthly intravenous gamma globulin should be started as soon as the diagnosis is made as this results in normal IgM levels and limits the number of severe and serious infections. However it may not prevent the opportunistic infections. In some cases it also improves growth.
Cotrimoxazole may be given prophylactically to prevent Pneumocystis jirovecii infection.
Granulocyte colony-stimulating factor (GCSF) treats the neutropenia.
Live vaccines should be avoided.
Bone marrow or umbilical cord stem cell transplant has been curative in some patients.
It has been suggested that affected boys should initially receive intravenous gamma globulin and cotrimoxazole with careful monitoring for complications of the disease. Bone marrow transplantation should be considered and performed if possible when complications develop.
See the DermNet NZ bookstore
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.